---
title: "Jyong Biotech tumbles 8% in regular trading"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/302899155.md"
description: "Jyong Biotech fell 8.05% to US$1.600. Down 29.07% over six months and down 59.24% YTD."
datetime: "2026-10-23T14:39:07.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/302899155.md)
  - [en](https://longbridge.com/en/news/302899155.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/302899155.md)
generator: "portal-rs"
---

# Jyong Biotech tumbles 8% in regular trading

Jyong Biotech (MENS.US) tumbled more than **8%** during regular trading to **$1.60**.

The stock is down 23.33% over the past ten sessions, down 29.07% over the past six months and down 59.24% year to date. It sits 97.46% below its 52-week high of US$63.00.

The Nasdaq Composite is down 0.48% over the past five sessions and up 11.92% year to date.

Based on public media reports. AI-generated; not investment advice.

### Related Stocks

- [MENS.US](https://longbridge.com/en/quote/MENS.US.md)

## Related News & Research

- [Jyong Biotech Plans Two-Day Investor Events](https://longbridge.com/en/news/302561057.md)
- [Jyong Biotech Plans Manufacturing Facility in Texas](https://longbridge.com/en/news/301975295.md)
- [Micron Stock (MU) Forecast – Why Are Analysts Bullish Despite Ongoing Volatility?](https://longbridge.com/en/news/305555924.md)
- [KHAZANCHI: H1 net income was ₹5,691.50 lakh; Q2 revenue was ₹60,557.54 lakh](https://longbridge.com/en/news/305540735.md)
- [FormFactor (FORM) Files A New Shelf, Is The Stock Still A Bargain?](https://longbridge.com/en/news/305535722.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**